PharmiWeb.com - Global Pharma News & Resources
PharmiWeb Today Story
Abbott Seeks Better Treatment Options for Patients With Both Atrial Fibrillation and Heart Failure With New Trial
- A new, first-of-its-kind study known as TAP-CHF leverages expertise across Abbott's cardiovascular portfolio to optimize treatment for patients suffering from both AFib and heart failure - The trial will utilize Abbott technology including cardiac ablation and sensors to monitor for both pulmonary artery pressure and abnormal heartbeats - Historically, treating patients with both AFib and heart failure has been challenging, with few effective treatments or options to adequately manage both conditions simultaneously

Abbott (NYSE: ABT) today announced a new trial focused on improving the treatment for people simultaneously battling both atrial fibrillation (AFib) and heart failure. The first-of-its-kind trial aims to provide new insights into more effective treatment for patients with AFib and heart failure, a complex combination that has historically presented significant challenges to physicians.

For many patients, cardiovascular disease can be exacerbated by comorbidities – additional problems requiring simultaneous management that make treatment of either condition more challenging. Clinical trials assessing therapies that can be deployed in tandem to better manage cardiovascular comorbidities are also rare. Few companies offer therapies across a clinical care spectrum that allows for the unique trial designs that can best provide physicians the insight they need to change the course of future care decisions.

The new TAP-CHF trial (Evaluating the Treatment of Atrial Fibrillation in Preserved Cardiac Function Heart Failure) aims to discover …

Read More...
Abbott Seeks Better Treatment Options for Patients With Both Atrial Fibrillation and Heart Failure With New Trial

Articles